MedPath

A study of peginterferon alfa-2a in combination with ribavirin in patients with chronic Hepatitis C.

Phase 3
Conditions
Chronic hepatitis C
Registration Number
JPRN-jRCT2080220023
Lead Sponsor
Chugai Pharmaceutical Co., Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Male and female patients and over 20 years of ages with CHC, elevated ALT and detectable HCV RNA.

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Efficacy and safety
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath